Tratamento da Depressão no Climatério

Autores/as

  • Renan Rocha Coordenador do Serviço de Saúde Mental da Mulher das Clínicas Integradas da Universidade do Extremo Sul Catarinense (UNESC).
  • Joel Rennó Jr Médico Psiquiatra. Diretor do Programa de Saúde Mental da Mulher (Pró-Mulher) do Instituto de Psiquiatria do Hospital das Clínicas da Universidade de São Paulo (USP). Doutor em Psiquiatria pela FMUSP. Membro fundador da International Association for Women’s Mental Health. Médico do Corpo Clínico do Hospital Israelita Albert Einstein-SP. https://orcid.org/0000-0003-1954-5898
  • Hewdy Lobo Ribeiro Psiquiatra Forense, Psicogeriatra e Psicoterapeuta pela Associação Brasileira de Psiquiatria. Psiquiatra no Pró-Mulher do Instituto de Psiquiatria da USP.
  • Amaury Cantilino Diretor do Programa de Saúde Mental da Mulher da UFPE. Professor Adjunto do Depto. de Neuropsiquiatria da UFPE.
  • Jerônimo de Almeida Mendes Ribeiro Médico Psiquiatra. Especialista em Psiquiatria pela Associação Brasileira de Psiquiatria. Pesquisador do Grupo de Psiquiatria - Transtornos Relacionados ao Puerpério, pela Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA).
  • Renata Demarque Médica Psiquiatra. Colaboradora do Programa de Saúde Mental da Mulher (Pró-Mulher) do Instituto de Psiquiatria do Hospital das Clínicas da Universidade de São Paulo (USP).
  • Juliana Pires Cavalsan Médica Psiquiatra. Colaboradora do Programa de Saúde Mental da Mulher (Pró-Mulher) do Instituto de Psiquiatria do Hospital das Clínicas da Universidade de São Paulo (USP).
  • Gislene Cristina Valadares Médica Psiquiatra pela Associação Brasileira de Psiquiatria. Mestre em Farmacologia e Bioquímica Molecular. Membro fundador do Serviço de Saúde Mental da Mulher do HC-UFMG, do Ambulatório de Acolhimento e Tratamento de Famílias Incestuosas (AMEFI, HC-UFMG), da Seção de Saúde Mental da Mulher da WPA e da International Association of Women’s Mental Health. https://orcid.org/0000-0001-8515-0937
  • Antonio Geraldo da Silva Psiquiatra. Especialista em Psiquiatria e Psiquiatria Forense pela ABP-AMB-CFM. Doutoramento em Bioética pela Universidade do Porto - CFM. Psiquiatra da Secretaria de Saúde do Distrito Federal - SES-DF. Diretor Científico do PROPSIQ. Presidente da ABP - 2010/2013. https://orcid.org/0000-0003-3423-7076

DOI:

https://doi.org/10.25118/2763-9037.2013.v3.338

Palabras clave:

depressão, climatério, tratamento

Resumen

No gênero feminino, a Depressão destaca-se em função de sua relevan-te prevalência ao longo dos anos reprodutivos. No climatério, principalmente na perimenopausa, há aumento significativo do número de casos, particularmente em associação com fogachos. Diversos antidepressivos demonstram eficácias semelhantes na população geral. Entretanto, pesquisas sugerem que é possível selecionar de modo mais criterioso e específico os medicamentos antide­ pressivos para pacientes que apresentam Transtorno Depressivo Maior no cli-matério associado a sintomas vasomotores.

Descargas

Los datos de descargas todavía no están disponibles.

Métricas

Cargando métricas ...

Citas

• 1. Soares C, Warren M. The menopausal transition: interface between gyne-cology and psychiatry. Key Issues Ment. Health. 2009;175:102-114. DOI: https://doi.org/10.1159/isbn.978-3-8055-9102-7

• 2. Soares C, Zitek B. Reproductive hormone sensitivity and risk for depresion across the female life cycle: a continuum of vulnerability J. Psychiatry Neuro-sci. 2008;33:331-43.

• 3. Clayton A, Ninan P. Depression or menopause? presentation and manage-ment of major depressive disorder in perimenopausal and postmenopausal women. Prim. Care Companion J. Clin. Psychiatry. 2010;12:1-13. DOI: https://doi.org/10.4088/PCC.08r00747blu

• 4. Deecher D, Andree T, Sloan D, Schechter L. From menarche to menopause: exploring the underlying biology of depression in women experiencing hormonal changes. Psychoneuroendocrinology. 2008; 33:3-17. DOI: https://doi.org/10.1016/j.psyneuen.2007.10.006

• 5. Cohen L, Soares C, Vitonis A, Otto M, Harlow B. Risk for new onset of de-pression during the menopausal transition: the harvard study of moods and cy-cles. Arch. Gen. Psychiatry. 2006;63:385-390. DOI: https://doi.org/10.1001/archpsyc.63.4.385

• 6. Freeman E, Sammel M, Lin H, Nelson D. Associations of hormones and men-opausal status with depressed mood in women with no history of depres-sion. Arch. Gen. Psychiatry. 2006;63:375-382. DOI: https://doi.org/10.1001/archpsyc.63.4.375

• 7. Roisin W, Susan R, Emorfia G, Zoe G, Stuart L, Henry B, Jayashri K. Hormo-nal therapies for new onset and relapsed depression during perimenopause. Maturitas. 2012;73:127-33. DOI: https://doi.org/10.1016/j.maturitas.2012.06.011

• 8. Narrow WE. Age and Gender Considerations In Psychiatric Diagnosis : A Research Agenda For DSM-V. 1ª ed. Arlington: Editora American Psychiatric Publishing; 2007.

• 9. Pinkerton J, Guico-Pabia C, Taylor H. Menstrual cycle-related exacerbation of disease. Am. J. Obstet. Gynecol. 2010;202:221-231. DOI: https://doi.org/10.1016/j.ajog.2009.07.061

• 10.Andrade L. Epidemiologia dos transtornos psiquiátricos na mulher. Rev. Psiq. Clín. 2006;33:43-54. DOI: https://doi.org/10.1590/S0101-60832006000200003

• 11. Society for Menstrual Cycle Research Position Statement Naming Women’s Midlife Reproductive Transition. [acessado em

10.2012]. Available from: http://menstruationresearch.org/wp-content/uploads/2012/04/SMCR-Position-statementPerimenopause-and-Menopause-reviewed-final.pdf

• 12. Soares C. Treatment of menopause-related mood disturbances. CNS. Spectr. 2005;10:489-497. DOI: https://doi.org/10.1017/S109285290002318X

• 13. Santoro N, Randolph J. Reproductive hormones and the menopause transi-tion. Obstet. Gynecol. Clin. N. Am. 2011;38:455-466. DOI: https://doi.org/10.1016/j.ogc.2011.05.004

• 14. Connolly K, Thase M. Emerging drugs for major depressive disorder. Expert Opin. Emerg. Drugs. 2012;17:105-26. DOI: https://doi.org/10.1517/14728214.2012.660146

• 15. Current Topics in Behavioral Neuroscience. Pharmacological Treatment of Unipolar Depression. [acessado em 17.10.2012]. Available from: http://link.springer.com/chapter/10.1007%2F7854_2012_208#page-1

• 16. Dunlop B, Binder E, Cubells J. Predictors of remission in depression to indi-vidual and combined treatments (PReDICT): study protocol for a randomized controlled trial. Trials. 2012;13:106. DOI: https://doi.org/10.1186/1745-6215-13-106

• 17. Thase M, Entsuah R, Cantillon M, Kornstein S. Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions. J. Womens Health (Larchmt). 2005;14:609-16. DOI: https://doi.org/10.1089/jwh.2005.14.609

• 18. Marsh W, Deligiannidis K. Sex-related differences in antidepressant re-sponse: When to adjust treatment. Current Psychiatry. 2010;9:25-31.

• 19. Neill JC, Kulkarni J. Biological Basis of Sex Differences in Psychopharma-cology. 1ª Ed. Berlin: Editora Springer‐Verlag; 2011. DOI: https://doi.org/10.1007/978-3-642-20006-9

• 20. Parry B. Optimal management of perimenopausal depression. Int. J. Wom-ens Health. 2010;2:143-51.• 21. Politi M, Schleinitz M, Col N. Revisiting the duration of vasomotor symptoms of menopause: a metaanalysis. J. Gen. Intern. Med. 2008;23:1507-13. DOI: https://doi.org/10.1007/s11606-008-0655-4

• 22. Minuzzi L, Frey B, Soares C. Depression during the menopausal transition: an update on epidemiology and biological treatments. Focus. 2012;10:22-27. DOI: https://doi.org/10.1176/appi.focus.10.1.22

• 23. Soares C, Thase M, Clayton A, Guico-Pabia C, Focht K, Jiang Q, Kornstein S, Ninan P, Kane C, Cohen L. Desvenlafaxine and escitalopram for the treat-ment of postmenopausal women with major depressive disorder. Meno-pause. 2010 ;17:700-11. DOI: https://doi.org/10.1097/gme.0b013e3181d88962

• 24. Wroolie T, Williams K, Keller J, Zappert L, Shelton S, Kenna H, Reynolds M, Rasgon N. Mood and neuropsychological changes in women with midlife depression treated with escitalopram. J. Clin. Psychopharmacol. 2006;26:361-6. DOI: https://doi.org/10.1097/01.jcp.0000227699.26375.f8

• 25. Freeman M, Hill R, Brumbach B. Escitalopram for perimenopausal depres-sion: an open-label pilot study. J. Womens Health (Larchmt). 2006;15:857-61. DOI: https://doi.org/10.1089/jwh.2006.15.857

• 26. Soares C, Arsenio H, Joffe H, Bankier B, Cassano P, Petrillo L, Cohen L. Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symp-toms, sleep, and quality of life. Menopause. 2006;13:780-6. DOI: https://doi.org/10.1097/01.gme.0000240633.46300.fa

• 27. Freeman E, Guthrie K, Caan B, Sternfeld B, Cohen L, Joffe H, Carpenter J, Anderson G, Larson J, Ensrud K, Reed S,Newton K, Sherman S, Sammel M, LaCroix A. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA. 2011;305:267-74. DOI: https://doi.org/10.1001/jama.2010.2016

• 28. Freedman RR, Kruger ML, Tancer ME. Escitalopram treatment of menopau-sal hot flashes. Menopause. 2011;18:893-6. DOI: https://doi.org/10.1097/gme.0b013e31820ccae9

• 29. Carpenter JS, Guthrie KA, Larson JC, Freeman EW, Joffe H, Reed SD, Ensrud KE, LaCroix AZ. Effect of escitalopram on hot flash

interference: a randomized, controlled trial. Fertil Steril. 2012;97:1399-404. DOI: https://doi.org/10.1016/j.fertnstert.2012.03.001

• 30. Lacroix AZ, Freeman EW, Larson J, Carpenter JS, Joffe H, Reed SD, Newton KM, Seguin RA, Sternfeld B, Cohen L, Ensrud KE. Effects of escitalopram on menopause-specific quality of life and pain in healthy meno-pausal women with hot flashes: A randomized controlled trial. Maturi-tas. 2012;73:361-8. DOI: https://doi.org/10.1016/j.maturitas.2012.09.006

• 31. Defronzo R, Menza M, Allen LA, Marin H, Bienfait KL, Tiu J, Howarth J. Es-citalopram reduces hot flashes in nondepressed menopausal women: A pilot study. Ann. Clin. Psychiatry. 2009;21:70-6.

• 32. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to an-tidepressants: a metaanalysis. J. Clin. Psychopharmacol. 2009;29:259-66. DOI: https://doi.org/10.1097/JCP.0b013e3181a5233f

• 33. Reed SD, Guthrie KA, Joffe H, Shifren JL, Seguin RA, Freeman EW. Sexual function in nondepressed women using escitalopram for vasomotor symptoms: a randomized controlled trial. Obstet. Gynecol. 2012;119:527-38. DOI: https://doi.org/10.1097/AOG.0b013e3182475fa4

• 34. Uher R, Mors O, Hauser J, Rietschel M, Maier W, Kozel D, et al. Changes in body weight during pharmacological treatment of depression. Int. J. Neuro-psychopharmacol. 2011;14:367-75. DOI: https://doi.org/10.1017/S1461145710000933

• 35. Wade A, Crawford G, Yellowlees A. Efficacy, safety and tolerability of es-citalopram in doses up to 50 mg in major depressive disorder (MDD): an open-label, pilot study. BMC Psychiatry. 2011;42:1-9. DOI: https://doi.org/10.1186/1471-244X-11-42

• 36. Gartlehner G, Gaynes BN, Hansen RA. Comparative benefits and harms of second-generation antidepressants: Background paper for the American Col-lege of Physicians. Ann. Intern. Med. 2008;149:734-750. DOI: https://doi.org/10.7326/0003-4819-149-10-200811180-00008

• 37. Trkulja V. Is escitalopram really relevantly superior to citalopram intreatment of major depressive disorder? A meta-analysis of head-to-head randomized trials. Croat. Med. J. 2010;51:61-73. DOI: https://doi.org/10.3325/cmj.2010.51.61

• 38. Montgomery S, Hansen T, Kasper S. Efficacy of escitalopram compared with citalopram: A metaanalysis. Int. J. Neuropsychopharmacol. 2011;14:261-8. DOI: https://doi.org/10.1017/S146114571000115X

• 39. Kornstein SG, Jiang Q, Reddy S, Musgnung JJ, Guico-Pabia CJ. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J. Clin. Psychiatry. 2010;71:1088-96. DOI: https://doi.org/10.4088/JCP.10m06018blu

• 40. A Multicenter, Parallel-Group, Randomized, 10-Week, Double-Blind, Place-bo-Controlled Study To Evaluate The Efficacy And Safety Of 50 mg Of DVS SR In The Treatment Of Peri- And Postmenopausal women With Major Depressive Disorder. [acessado em 09.04.2012]. Available from: http://www.clinicaltrials.gov/ct2/home

• 41. Kornstein SG, Clayton AH, Soares CN, Padmanabhan SK, Guico-Pabia CJ. Analysis by age and sex of efficacy data from placebo-controlled trials of desvenlafaxine in outpatients with major depressive disorder. J. Clin. Psycho-pharmacol. 2010;30:294-9. DOI: https://doi.org/10.1097/JCP.0b013e3181dcb594

• 42. Soares CN, Thase ME, Clayton A, Guico-Pabia CJ, Focht K, Jiang Q, Kornstein SG, Ninan PT, Kane CP. Open-label treatment with desvenlafaxine in postmenopausal women with majordepressive disorder not responding to acute treatment with desvenlafaxine or escitalopram. CNS Drugs. 2011;25:227-38. DOI: https://doi.org/10.2165/11586460-000000000-00000

• 43.Wyrwich KW, Spratt DI, Gass M, Yu H, Bobula JD. Identifying meaningful differences in vasomotor symptoms among menopausal women. Meno-pause. 2008;15:698-705. DOI: https://doi.org/10.1097/gme.0b013e31815f892d

• 44. Speroff L, Gass M, Constantine G, Olivier S; Study 315 Investigators. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vaso-motor symptoms: a randomized controlled trial. Obstet. Gynecol. 2008;111:77-87. DOI: https://doi.org/10.1097/01.AOG.0000297371.89129.b3

• 45. Archer DF, Dupont CM, Constantine GD, Pickar JH, Olivier S. Desvenlafax-ine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. Am. J. Obstet. Gynecol. 2009;238:1-10. DOI: https://doi.org/10.1016/j.ajog.2008.10.057

• 46. Pinkerton JV, Constantine G, Hwang E, Cheng RF; for the Study 3353 In-vestigators. Desvenlafaxine compared with placebo for treatment of menopau-sal vasomotor symptoms: a 12-week, multicenter, parallelgroup, randomized, double-blind, placebo-controlled efficacy trial. Menopause. [periódico online] 2012; [acessado em 02.09.2012]. Disponível em: http://www.ncbi.nlm.nih.gov/pubmed/23010882

• 47. Archer DF, Dupont CM, Constantine GD, Pickar JH, Olivier S; Study 319 Investigators. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am. J. Obstet. Gynecol. 2009;200:1-10. DOI: https://doi.org/10.1016/j.ajog.2008.09.877

• 48. Bouchard P, Panay N, de Villiers TJ, Vincendon P, Bao W, Cheng RJ, Constantine G. Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms. Climacteric. 2012;15:12-20. DOI: https://doi.org/10.3109/13697137.2011.586445

• 49. Cheng RJ, Dupont C, Archer DF, Bao W, Racketa J, Constantine G, Pickar JH. Effect of desvenlafaxine on mood and climacteric symptoms in menopausal women with moderate to severe vasomotor symptoms. Climacteric. 2012;10:1-11. DOI: https://doi.org/10.3109/13697137.2012.672495

• 50. Dunlop BW, Reddy S, Yang L, Lubaczewski S, Focht K, Guico-Pabia CJ. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. J. Clin. Psycho-pharmacol. 2011;31:569-76. DOI: https://doi.org/10.1097/JCP.0b013e31822c0a68

• 51. Tourian KA, Leurent C, Graepel J, Ninan PT. Desvenlafax-ine and weight change in major depressive disorder. Prim. Care Companion J. Clin. Psychiatry. 2010;12:1-8. DOI: https://doi.org/10.4088/PCC.08m00746blu

• 52. Ferguson JM, Tourian KA, Rosas GR. High-dose desvenlafaxine in outpa-tients with major depressive disorder. CNS Spectr. 2012;17:121-30. DOI: https://doi.org/10.1017/S1092852912000508

• 53. Coleman KA, Xavier VY, Palmer TL, Meaney JV, Radalj LM, Canny LM.An indirect comparison of the efficacy and safety of desvenlafaxine and venlafaxine using placebo as the common comparator. CNS Spectr. 2012;17:131-41. DOI: https://doi.org/10.1017/S1092852912000648

• 54. Marsh WK, Deligianiddis KM. Sex-related differences in antidepressant re-sponse: When to adjust treatment. Current Psychiatry. 2010; 9:25-31.

• 55. Weinberger AH, McKee SA, Mazure CM. Inclusion of women and gender-specific analyses in randomized clinical trials of treatments for depression. J. Womens Health (Larchmt). 2010;19:1727-32. DOI: https://doi.org/10.1089/jwh.2009.1784

• 56. Simon GE, Perlis RH. Personalized medicine for depression: Can we match patients with treatments? Am. J. Psychiatry. 2010;167:1445-1455. DOI: https://doi.org/10.1176/appi.ajp.2010.09111680

• 57. Abramowicz M. Drugs for menopausal symptoms. Med. Lett. Drugs Ther. 2012;54:41-2.

• 58. Santoro NF, Clarkson TB, Freedman RR, FughBerman AJ, Loprinzi CH, Reame NC. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause. 2004;11:11-33. DOI: https://doi.org/10.1097/01.GME.0000108177.85442.71

• 59. Cobin RH, Futterweit W, Ginzburg SB, Goodman NF, Kleerekoper M, Licata AA et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause. Endocr. Pract. 2006;12:315-337. DOI: https://doi.org/10.4158/EP.12.3.315

• 60. Umland EM. Treatment strategies for reducing the burden of menopause-associated vasomotor symptoms. J Manag Care Pharm. 2008;14:14-19. DOI: https://doi.org/10.18553/jmcp.2008.14.S3-A.14

• 61. U.S. Department of Health and Human Services - Food and Drug Admin-istration. Guidance for industry: estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms - recommendations for clinical evaluation. [acessado em 02.12.2012]. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM135338.pdf

• 62. European Medicines Agency. Guideline on clinical investigation of medicinal products for hormone replacement therapy of oestrogen deficiency symptoms in postmenopausal women. [acessado em 03.12.2012]. Available from: http://www.tga.gov.au/pdf/euguide/emea002197enrev1.pdf

Descargas

Publicado

2013-02-28

Cómo citar

1.
Rocha R, Rennó Jr J, Ribeiro HL, Cantilino A, Ribeiro J de AM, Demarque R, Cavalsan JP, Valadares GC, Silva AG da. Tratamento da Depressão no Climatério. Debates em Psiquiatria [Internet]. 28 de febrero de 2013 [citado 22 de diciembre de 2024];3(1):18-25. Disponible en: https://revistardp.org.br/revista/article/view/338

Número

Vol. 3 Núm. 1 (2013)

Sección

Artículo de revisión

Licencia

Creative Commons License

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.

Debates em Psiquiatria permite que el (los) autor (es) mantenga(n) sus derechos de autor sin restricciones. Permite al (los) autor (es) conservar sus derechos de publicación sin restricciones. Los autores deben garantizar que el artículo es un trabajo original sin fabricación, fraude o plagio; no infringe ningún derecho de autor o derecho de propiedad de terceros. Los autores también deben garantizar que cada uno atendió a los requisitos de autoría conforme a la recomendación del ICMJE y entienden que, si el artículo o parte de él es fallido o fraudulento, cada autor comparte la responsabilidad.

Reconocimiento-NoComercial 4.0 internacional (CC BY-NC 4.0) - Debates em Psiquiatria es regida por la licencia CC-BY-NC
Usted es libre de:

  • Compartir — copiar y redistribuir el material en cualquier medio o formato
  • Adaptar — remezclar, transformar y crear a partir del material

El licenciador no puede revocar estas libertades mientras cumpla con los términos de la licencia. Bajo las condiciones siguientes:

  • Reconocimiento — Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios<. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.
  • NoComercial — No puede utilizar el material para una finalidad comercial.

No hay restricciones adicionales — No puede aplicar términos legales o medidas tecnológicas que legalmente restrinjan realizar aquello que la licencia permite.

Crossref
Scopus
Google Scholar
Europe PMC

Plaudit

Artículos similares

También puede {advancedSearchLink} para este artículo.

Artículos más leídos del mismo autor/a

1 2 3 4 5 6 7 8 9 10 > >>